SYNGENE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | SYNGENE | Market Cap | 18,843 Cr. | Current Price | 468 ₹ | High / Low | 729 ₹ |
| Stock P/E | 52.1 | Book Value | 117 ₹ | Dividend Yield | 0.27 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 440 ₹ | DMA 200 | 552 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 65.4 | MACD | 7.54 | Volume | 6,33,89,388 | Avg Vol 1Wk | 1,66,63,242 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -6.19 | Debt to equity | 0.04 |
| 52w Index | 25.1 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 39.6 |
📈 Chart Patterns & Trend: SYNGENE is trading above its 50 DMA (₹440) but below its 200 DMA (₹552), with current price at ₹468. This indicates short-term strength but medium-term weakness. The stock is consolidating with mild bullish bias, supported by recent price action.
📊 Indicators: RSI at 65.4 suggests approaching overbought territory. MACD positive at 7.54 confirms bullish crossover. Bollinger Bands show price near upper band, signaling momentum but also risk of pullback.
🔎 Volume: Current volume (6.33 Cr.) is significantly higher than average weekly volume (1.66 Cr.), showing strong participation and accumulation interest.
🎯 Entry Zone: ₹455–₹465 (near 50 DMA support)
🚪 Exit Zone: ₹490–₹500 (resistance zone, short-term target)
Positive
- Strong quarterly PAT growth (₹154 Cr. vs ₹68.7 Cr.).
- EPS of ₹7.57 supports earnings visibility.
- Low debt-to-equity ratio (0.04) ensures financial stability.
- DII holdings increased by 0.61%, showing domestic confidence.
Limitation
- High P/E of 52.1 compared to industry average (39.6), indicating premium valuation.
- ROCE (10.0%) and ROE (7.74%) remain modest.
- PEG ratio of -6.19 suggests poor valuation alignment with growth.
- FII holdings decreased by 1.05%, showing reduced foreign interest.
Company Negative News
- Quarterly profit variation of -11.8% highlights earnings volatility.
- Premium valuation may limit upside if growth slows.
Company Positive News
- Strong sequential PAT growth supports near-term momentum.
- Domestic institutional investors increased stake, reflecting confidence.
Industry
- Industry PE at 39.6 is lower than SYNGENE’s 52.1, highlighting premium valuation.
- Biotech and pharma sector outlook remains positive with demand recovery and R&D investments.
Conclusion
SYNGENE is consolidating with short-term bullish signals from MACD, RSI, and strong volume. Entry near ₹455–₹465 offers favorable risk-reward, with exit around ₹490–₹500. Fundamentals remain stable, but high valuations and modest efficiency metrics require cautious positioning.
Would you like me to also prepare a sector overlay comparison (benchmarking SYNGENE against peers like DIVISLAB, BIOCON, and LAURUSLABS) to highlight relative strength and valuation positioning?